The effect of general and spinal anesthesia on the level of inflammatory factors in hysterectomy surgery

Comparison of the effect of general and spinal anesthesia on serum level of pro-inflammatory and anti-inflammatory factors after abdominal hysterectomy surgery: a non-randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190819044559N4

Enrollment

Registered

2023-01-31

Start date

2022-12-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory factors after hysterectomy. Abnormal uterine and vaginal bleeding, unspecified

Interventions

Intervention 1: Intervention group: patients receive spinal anesthesia (20 micrograms of fentanyl, 20 micrograms of bupivacaine and 10 micrograms of epinephrine). Intervention 2: Control group: Patien

Eligibility

Sex/Gender

Female

Age

35 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients who will undergo hysterectomy with different diagnoses are included in the study.

Exclusion criteria

Exclusion criteria: Patients with a history of any type of inflammatory and autoimmune disease History of endocrine diseases Severe neurological disease Corticosteroid use in the three months before surgery Evidence of any infectious disease

Design outcomes

Primary

Measure	Time frame
IL -17 serum level. Timepoint: Before intervention, 48 hours after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;IL-2 serum level. Timepoint: Before intervention, 48 hours after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;IL -6 serum level. Timepoint: Before intervention, 48 hours after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;TNF -a serum level. Timepoint: Before intervention, 48 hours after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;IL-10 serum level. Timepoint: Before intervention, 48 hours after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).	—

Measure

Time frame

IL -17 serum level. Timepoint: Before intervention, 48 hours after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;IL-2 serum level. Timepoint: Before intervention, 48 hours after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;IL -6 serum level. Timepoint: Before intervention, 48 hours after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;TNF -a serum level. Timepoint: Before intervention, 48 hours after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;IL-10 serum level. Timepoint: Before intervention, 48 hours after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Hashemian

Kerman University of Medical Sciences

mortezahashemian@kmu.ac.ir+98 34 3223 5011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026